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Abstract
The aim of this study was to implement massive parallel sequencing (MPS) technology in clinical
genetics testing. We developed and tested an amplicon-based method for resequencing the
BRCA1 and BRCA2 genes on an Illumina MiSeq to identify disease-causing mutations in patients
with hereditary breast or ovarian cancer (HBOC). The coding regions of BRCA1 and BRCA2 were
resequenced in 96 HBOC patient DNA samples obtained from different sample types: peripheral
blood leukocytes, whole blood drops dried on paper, and buccal wash epithelia. A total of 16
random DNA samples were characterized using standard Sanger sequencing and applied to
optimize the variant calling process and evaluate the accuracy of the MPS-method. The best
bioinformatics workflow included the filtration of variants using GATK with the following cut-offs:
variant frequency > 14%, coverage ( > 25×) and presence in both the forward and reverse
reads. The MPS method had 100% sensitivity and 94.4% specificity. Similar accuracy levels were
achieved for DNA obtained from the different sample types. The workflow presented herein
requires low amounts of DNA samples (170 ng) and is cost-effective due to the elimination of
DNA and PCR product normalization steps.
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